Skip to main content

Table 2 Cox analysis of prognostic factors in MuBC patients in the training queue

From: Nomogram for predicting survival in patients with mucinous breast cancer undergoing chemotherapy and surgery: a population-based study

Characteristics

Univariate analysis

Multivariable analysis

 

HR (95% CI)

P-value

HR (95% CI)

P-value

Age

    

 ≤ 52

Reference

 

Reference

 

 > 52

2.081 (1.514–2.862)

 < 0.001*

1.980 (1.437–2.728)

 < 0.001*

Breast subtype

    

 HR+/HER-2−

Reference

   

 HR+/HER-2+

1.028 (0.505–2.091)

0.940

  

 HR−/HER-2+

0.613 (0.084–4.490)

0.630

  

 HR−/HER-2−

0.000 (0.000–infinity)

0.951

  

 Unknown

1.016 (0.670–1.541)

0.940

  

Stage

    

 I

Reference

 

Reference

 

 II

1.625 (1.097–2.408)

0.015*

1.682 (1.097–2.580)

0.017*

 III

2.684 (1.690–4.262)

 < 0.001*

2.752 (1.382–5.479)

0.004*

 IV

10.772 (5.321–21.808)

 < 0.001*

6.642 (1.962–22.491)

0.002*

ER status

    

 Negative

Reference

   

 Positive

0.634 (0.373–1.077)

0.092

  

PR status

    

 Negative

Reference

   

 Positive

0.830 (0.576–1.195)

0.316

  

HER-2 status

    

 Negative

Reference

   

 Positive

0.994 (0.501–1.972)

0.986

  

 Unknown

1.044 (0.688–1.583)

0.841

  

Historic stage

    

 Localized

Reference

 

Reference

 

 Regional

1.309 (0.946–1.811)

0.104

0.754 (0.483–1.177)

0.213

 Distant

5.382 (3.158–9.172)

 < 0.001*

1.449 (0.535–3.925)

0.466

Surgery

    

 BCS

Reference

 

Reference

 

 Mastectomy

0.997 (0.643–1.545)

0.989

0.779 (0.478–1.270)

0.316

 Radical

2.069 (1.483–2.887)

 < 0.001*

1.343 (0.893–2.019)

0.157

Radiotherapy

    

 No

Reference

 

Reference

 

 Yes

0.741 (0.548–1.003)

0.053

0.727 (0.511–1.036)

0.078

  1. HR hormone receptors, HER-2 human epidermal growth factor receptor 2, ER estrogen receptor, PR progesterone receptor, BCS breast-conserving surgery
  2. *P < 0.05